Grifols Expansion Plans Include Biotech Equity, New US Manufacturing Facilities
Taking a 20% equity stake in US biotech Singulex and planning to build new manufacturing facilities in the US and Europe reflect the global expansion plans of Spain’s plasma product manufacturer Grifols, the third-largest in the world.
You may also be interested in...
After a string of failures, Winston-Salem, North Carolina-based Targacept and its neuronal nicotinic receptor (NNR) therapeutics will be replaced by engineered human proteases for hemophilia and complement-mediated disorders in a reverse merger with privately-held Catalyst Biosciences in South San Francisco.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.